

Alissa Visram

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5842037/publications.pdf>

Version: 2024-02-01

34
papers

174
citations

1163117

8
h-index

1199594

12
g-index

35
all docs

35
docs citations

35
times ranked

279
citing authors

#	ARTICLE	IF	CITATIONS
1	Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. <i>Blood Cancer Journal</i> , 2021, 11, 45.	6.2	24
2	Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. <i>Blood Cancer Journal</i> , 2021, 11, 120.	6.2	18
3	Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies. <i>Leukemia Research</i> , 2020, 97, 106442.	0.8	15
4	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 596-601.	0.4	15
5	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021, 56, 1144-1150.	2.4	15
6	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. <i>Blood Cancer Journal</i> , 2022, 12, 67.	6.2	13
7	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, 124.	6.2	12
8	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 1428-1437.	7.2	8
9	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021, 11, 186.	6.2	8
10	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥ 100 . <i>Leukemia</i> , 2022, 36, 1429-1431.	7.2	8
11	Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2466-2470.	2.0	7
12	Outcomes after biochemical or clinical progression in patients with multiple myeloma. <i>Blood Advances</i> , 2023, 7, 909-917.	5.2	7
13	Aging-associated immune system changes in multiple myeloma: The dark side of the moon.. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100494.	1.7	6
14	Colon perforation in multiple myeloma patients – A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020, 9, 8895-8901.	2.8	3
15	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. <i>Leukemia</i> , 2022, 36, 1058-1065.	7.2	3
16	Outcomes of multiple myeloma patients with $\text{del } 17p$ undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, E35-E38.	4.1	2
17	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021, 62, 316-322.	1.3	2
18	Treatment and outcome of newly diagnosed multiple myeloma patients ≥ 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Describing the Cellular and Humoral Immune Tumor Microenvironment and Malignant Transcriptome across the Multiple Myeloma Disease Spectrum. <i>Blood</i> , 2020, 136, 39-40.	1.4	2
20	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 274-277.	2.4	1
21	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 309.e1-309.e5.	1.2	1
22	Practical management and assessment of primary plasma cell leukemia in the novel agent era. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100414.	1.7	1
23	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 3760-3760.	1.4	1
24	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021, 138, 2700-2700.	1.4	0
25	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥ 100 . <i>Blood</i> , 2021, 138, 1617-1617.	1.4	0
26	Prognostic Factors for Early (≤ 2 years) and Late (> 5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , 2021, 138, 3761-3761.	1.4	0
27	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , 2021, 138, 543-543.	1.4	0
28	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients ≥ 75 Years Old: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
29	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 21-22.	1.4	0
30	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents. <i>Blood</i> , 2020, 136, 12-13.	1.4	0
31	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , 2020, 136, 37-38.	1.4	0
32	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 1-2.	1.4	0
33	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 41-42.	1.4	0
34	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. <i>Bone Marrow Transplantation</i> , 2022, , .	2.4	0